News and Trends 14 Nov 2022 Priothera’s Mocravimod improves survival for patients with hematological malignancies Priothera, a biotechnology company developing its S1P receptor modulator compound Mocravimod, has announced that positive data from a clinical trial reinforces the potential for the drug to improve survival outcomes for patients with hematological malignancies. The study has been evaluating Mocramivod in allogeneic hematopoietic cell transplantation patients and was published in journal Transplantation and Cellular […] November 14, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 EpiEndo gets regulatory approval for first patient study of first non-antibiotic macrolide EpiEndo Pharmaceuticals, a clinical-stage biopharma company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to begin a phase 2a clinical trial. The trial will be with lead molecule EP395 in COPD (chronic obstructive pulmonary disease) patients, an orally available macrolide or ‘Barriolide,’ with reduced antimicrobial resistance potential. It aims to address the unmet […] November 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 14 Nov 2022 MaaT Pharma: leading the charge in microbiome therapeutics The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business officer at the French biotech MaaT Pharma outlines the firm’s efforts to blaze a trail in clinical testing and manufacturing in the new field. The microbiome world recently made a regulatory step forward as Australia greenlit a stool transplant developed […] November 14, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Eden Bio raises £1m to boost AI protein yields Eden Bio, a U.K.-based biotech using machine learning to increase protein yield, has raised £1 million ($1.17 million) from a seed investment round. The company said this strengthens its R&D capacity and ability to expand the underlying machine-learning platform over the coming years. By using artificial intelligence to genetically optimize microorganism strains, the company improves […] November 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 14 Nov 2022 33 Californie launches new fund for healthcare startups 33 Californie, an investment fund specialized in the healthcare sector, has opened subscriptions for CaLySeed, its second investment fund, providing financial and strategic support to start-ups. The aim of the new initiative is to finance innovations in human health, including therapeutics, medical devices, in vitro diagnostics, e-health, technology platforms and nutraceuticals. CaLySeed will invest in […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 14 Nov 2022 ChromaTwist lands second round of funding for fluorescent dyes for flow cytometry market ChromaTwist Ltd, a University of Birmingham spinout, has secured £487,000 ($573,000) of equity investment to develop its new class of fluorescent dyes for the flow cytometry reagent market. Existing investors, Angel from angelgroups and the University of Birmingham brought in funds which will allow ChromaTwist to continue product development with industry partners and enable rapid […] November 14, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 A new treatment for tackling epidermolysis bullosa By Jordi Casals, president, EMEA, Amryt Pharma Epidermolysis bullosa (EB), sometimes described as “the worst disease you’ve never heard of,” is a group of rare and distressing inherited skin disorders primarily diagnosed in young children. The genetic mutations that cause EB can result in the skin being extremely fragile. Any physical contact with the skin […] November 14, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Altered cell behavior reason for neuroblastoma resistance Researchers at Lund University in Sweden have identified one of the reasons why the childhood cancer neuroblastoma becomes resistant to chemotherapy. The scientists hope the findings are significant for how future treatments should be designed. The results have been published in the journal Science Advances. Neuroblastoma is an aggressive cancer of the sympathetic nervous system, […] November 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 New therapy transitions toxic immune cells from harmful to healing to fight effects of hyperinflammation in children When we think about acute kidney injury (AKI) and multi-organ failure, we don’t often think about children. But approximately 4,000 pediatric patients in the U.S. each year have AKI requiring continual kidney replacement therapy (CKRT). These patient profiles are associated with long hospital stays, high morbidity and mortality (50%), and children who survive an AKI […] November 14, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 InfanDx tackles early detection of hypoxic ischemic encephalopathy InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, has completed the validation of metabolic biomarker panels for the early detection of hypoxic ischemic encephalopathy (HIE) in newborns. The validated biomarkers of such panels will be the target of the company’s HypoxE blood test for […] November 14, 2022 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 RSV cases are rising fast in children. Early detection can help. By Shawn Gaskell, MilliporeSigma RSV-related hospitalizations for 2022 have already surged to unusually high numbers, surpassing cumulative cases typically reported in late December each year, and we’re not even one month into the season. While no age group is immune to RSV— respiratory syncytial virus— and the trouble it can cause, young children are being […] November 14, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 14 Nov 2022 In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term […] November 14, 2022 - 9 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email